Articles with public access mandates - Oscar krijgsmanLearn more
Not available anywhere: 3
Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
J Boshuizen, LA Koopman, O Krijgsman, A Shahrabi, EG van den Heuvel, ...
Nature Medicine 24 (2), 203-212, 2018
Mandates: European Commission, Dutch Cancer Society
Cooperative targeting of immunotherapy-resistant melanoma and lung cancer by an AXL-targeting antibody–drug conjugate and immune checkpoint blockade
J Boshuizen, N Pencheva, O Krijgsman, DDE Altimari, PG Castro, ...
Cancer research 81 (7), 1775-1787, 2021
Mandates: European Commission, Dutch Cancer Society
Detailed imaging and genetic analysis reveal a secondary BRAFL505H resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant …
M Hoogstraat, CG Gadellaa‐van Hooijdonk, I Ubink, NJM Besselink, ...
Pigment cell & melanoma research 28 (3), 318-323, 2015
Mandates: Dutch Cancer Society
Available somewhere: 37
B cells and tertiary lymphoid structures promote immunotherapy response
BA Helmink, SM Reddy, J Gao, S Zhang, R Basar, R Thakur, K Yizhak, ...
Nature 577 (7791), 549-555, 2020
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
J Müller, O Krijgsman, J Tsoi, L Robert, W Hugo, C Song, X Kong, ...
Nature communications 5 (1), 5712, 2014
Mandates: US National Institutes of Health, European Commission, Dutch Cancer Society
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2 …
EA Rozeman, AM Menzies, ACJ van Akkooi, C Adhikari, C Bierman, ...
The Lancet Oncology 20 (7), 948-960, 2019
Mandates: National Health and Medical Research Council, Australia
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
EA Rozeman, EP Hoefsmit, ILM Reijers, RPM Saw, JM Versluis, ...
Nature medicine 27 (2), 256-263, 2021
Mandates: National Health and Medical Research Council, Australia
Restricting glycolysis preserves T cell effector functions and augments checkpoint therapy
K Renner, C Bruss, A Schnell, G Koehl, HM Becker, M Fante, ...
Cell reports 29 (1), 135-150. e9, 2019
Mandates: US National Institutes of Health, German Research Foundation
CopywriteR: DNA copy number detection from off-target sequence data
T Kuilman, A Velds, K Kemper, M Ranzani, L Bombardelli, M Hoogstraat, ...
Genome biology 16, 1-15, 2015
Mandates: Cancer Research UK, Wellcome Trust, Dutch Cancer Society
Augmenting immunotherapy impact by lowering tumor TNF cytotoxicity threshold
DW Vredevoogd, T Kuilman, MA Ligtenberg, J Boshuizen, KE Stecker, ...
Cell 178 (3), 585-599. e15, 2019
Mandates: Netherlands Organisation for Scientific Research, European Commission, Dutch …
A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response
O Krijgsman, P Roepman, W Zwart, JS Carroll, S Tian, FA de Snoo, ...
Breast cancer research and treatment 133, 37-47, 2012
Mandates: Cancer Research UK
Intra‐and inter‐tumor heterogeneity in a vemurafenib‐resistant melanoma patient and derived xenografts
K Kemper, O Krijgsman, P Cornelissen‐Steijger, A Shahrabi, F Weeber, ...
EMBO molecular medicine 7 (9), 1104-1118, 2015
Mandates: Cancer Research UK, Wellcome Trust, European Commission, Dutch Cancer Society
TSPYL5 suppresses p53 levels and function by physical interaction with USP7
MT Epping, LAT Meijer, O Krijgsman, JL Bos, PP Pandolfi, R Bernards
Nature cell biology 13 (1), 102-108, 2011
Mandates: US National Institutes of Health
Transcription factor NFIB is a driver of small cell lung cancer progression in mice and marks metastatic disease in patients
EA Semenova, M Kwon, K Monkhorst, JY Song, R Bhaskaran, ...
Cell reports 16 (3), 631-643, 2016
Mandates: Netherlands Organisation for Scientific Research, European Commission, Dutch …
Integrative epigenetic taxonomy of primary prostate cancer
S Stelloo, E Nevedomskaya, Y Kim, K Schuurman, E Valle-Encinas, ...
Nature communications 9 (1), 4900, 2018
Mandates: Netherlands Organisation for Scientific Research, Dutch Cancer Society
XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data
RJC Kluin, K Kemper, T Kuilman, JR de Ruiter, V Iyer, JV Forment, ...
BMC bioinformatics 19, 1-15, 2018
Mandates: UK Biotechnology and Biological Sciences Research Council, Cancer Research …
Reversal of pre-existing NGFR-driven tumor and immune therapy resistance
J Boshuizen, DW Vredevoogd, O Krijgsman, MA Ligtenberg, ...
Nature communications 11 (1), 3946, 2020
Mandates: European Commission, Dutch Cancer Society
BRAFV600E kinase domain duplication identified in therapy-refractory melanoma patient-derived xenografts
K Kemper, O Krijgsman, X Kong, P Cornelissen-Steijger, A Shahrabi, ...
Cell reports 16 (1), 263-277, 2016
Mandates: Netherlands Organisation for Scientific Research, Cancer Research UK …
Comprehensive analysis of cutaneous and uveal melanoma liver metastases
EP Hoefsmit, EA Rozeman, TM Van, P Dimitriadis, O Krijgsman, ...
Journal for immunotherapy of cancer 8 (2), 2020
Mandates: National Health and Medical Research Council, Australia
High-risk human papillomavirus–positive lung cancer: molecular evidence for a pattern of pulmonary metastasis
RAA van Boerdonk, JMA Daniels, E Bloemena, O Krijgsman, ...
Journal of Thoracic Oncology 8 (6), 711-718, 2013
Mandates: Dutch Cancer Society
Publication and funding information is determined automatically by a computer program